Introduction
Well designed prospective cohort studies have considerable utility in identifying genetic and environ mental risk factors for an array of somatic and psychiatric disorders. In the many contexts in which randomised controlled trials are not feasible owing to financial, ethical, or logistical constraints, this type of observational study provides the best approximation of causality. Although well phenotyped cohort stu dies have existed for decades, recent technological advances have led to low cost, high throughput methods to quantify genetic variation. Simultaneously expanding prospects for linkage to medical and non medical electronic records has allowed construction of studies with the capacity to explore the effect of gene environment combinations on health endpoints at a previously unheralded scale. Several countries have established such national "biobanks," 1 2 are in the process of their formulation, 35 or are planning such an endeavour. 6 One such leading resource is UK Biobank, a prospective cohort study comprising around 500 000 middle aged and older people. 7 Unusually in the context of medical research, baseline data have been open access since completion of curation in 2012, 8 and, to date, the study has yielded in excess of 1000 publications. 9 Although UK Biobank is rare in its combination of size and content, it also had an uncommonly low response to its baseline survey: of more than nine million people sent an invitation to participate, only around 6% did so. 10 This achieved response rate was driven by the cost and time saving doi: 10.1136/bmj.m131 | BMJ 2020;368:m131 | the bmj decision not to recontact undecided potential participants. 11 Presumably as a consequence, the project came in under budget and ahead of schedule.
Whereas such an approach is doubtless procedurally efficient, the long held view is that epidemiological studies need to achieve considerably higher response rates if their findings are to be credible. 12 13 Debates about the effect of nonresponse on estimations of chronic disease determinants in UK Biobankits primary objective-and the wider necessity for representativeness have followed. 1423 Despite more favourable baseline risk factor levels and mortality rates in UK Biobank relative to studies achieving a greater response, 24 its principal investigators have consistently maintained that, because the exposures of interest have sufficient variance and the study sample is large, the generalisability of associations between risk factors and health outcomes is assured. 11 25 26 Although findings from cohort studies sampled from highly select groups-Framingham residents and British civil servants, 27 28 among many others 29provide indirect support for this assertion, to our knowledge it has yet to be tested empirically.
To examine whether risk factor associations in UK Biobank are generalisable, in analyses of raw data from the study, we compared effect estimates for characteristics known to be linked to major causes of mortality against those from a pooling of data from nationally sampled cohort studies drawn from England and Scotland, all of which had a conventional response to their baseline surveys (mean 68%). 30 With UK Biobank data being deployed across a range of scientific disciplines, we also chose an array of mortality endpoints and exposures. Given the nature of our research question, our focus was not on discovery of risk factors; rather, our aim was to test risk factorendpoint associations that are well established on the basis of strong observational and/or experimental evidence. We therefore related demographic, social, behavioural, and biomedical risk factors to cardiovascular disease, 31 32 physical stature to cardiovascular disease and cancer, 3335 and educational attainment to suicide risk .3639
Methods
We used individual level data from both UK Biobank, 7 a prospective cohort study, and a pooling of 18 other prospective cohort studies with identical core protocols: the Health Survey for England (HSE; 15 studies) 40 and the Scottish Health Surveys (SHS; three studies) 41 (hereafter, HSESHS). The sampling and procedures of these studies have been well described. 42 43 In brief, baseline data collection in UK Biobank took place between 2006 and 2010 in 22 research assessment centres across the UK, resulting in a sample of 502 655 people aged 40 to 69 years (response rate 5.5%). 7 In HSE and SHS, a total of 193 842 people aged 16102 years (mean response rate 68%; range 5893% 30 ) participated in home based data collection between 1994 and 2008. For the purposes of this comparison, we restricted HSESHS data to the 89 895 people (48 364 women) with a baseline age range that matched UK Biobank. Participants in both studies gave informed consent.
assessment of baseline characteristics
In both UK Biobank and HSESHS, the following data were selfreported using identical or near identical enquiries: diagnosis by a physician of chronic disease (diabetes, hypertension, cardiovascular disease); use of multivitamins, lipid lowering drugs, blood glucose lowering drugs, and antihypertensive drugs; educa tional attainment; cohabitation status; and cigarette smoking habit. Although physical activity and alcohol intake were collected using somewhat different questions, we were able to derive comparable binary categories (current nondrinker versus the rest; physically inactive versus the rest).
During medical examinations, waist and hip circumference, as well as height and weight, were measured directly using standard protocols. Elevated waist:hip ratio was denoted by values of 0.90 or greater for men and 0.85 or greater for women 44 ; obesity was indicated by a body mass index of 30 or above. 45 Forced expiratory volume in one second, a measure of pulmonary function, was quantified using spirometry with the best of three (UK Biobank) or five (HSESHS) technically satisfactory exhalations used in our analyses. In UK Biobank, seated systolic and diastolic blood pressure measurements were made twice using the Omron HEM7015IT digital blood pressure monitor (Omron Healthcare) 20 or, exceptionally, a manual sphygmomanometer (6652 people); we used an average of the two readings. In HSESHS, three readings were taken using the Dinamap 8100 automated device, 46 with a mean of the second and third values featuring in our analyses. We defined hypertension according to existing guidelines as systolic/diastolic blood pressure of 140/90 mm Hg or above, selfreported use of antihypertensive drugs, or both. 47 Nonfasting venous blood was drawn in both studies. 48 49 Assaying took place at dedicated central laboratories for C reactive protein, glycated haemoglobin, and total cholesterol and high density lipoprotein cholesterol. 40 48 ascertainment of cause specific mortality Participants in both studies were linked to mortality registries by using the procedures of the UK National Health Service Central Registry. 50 We extracted underlying cause of death, coded according to ICD 10 (international classification of disease, 10th revision), from death certificate data. 50 We generated the following mortality outcomes: cardiovascular disease, all cancers combined, lung cancer, smoking attributable cancers, obesity attributable cancers, and suicide. The ICD codes denoting these causes of death are given in supplemental table 1.
statistical analyses
We calculated hazard ratios and accompanying 95% confidence intervals by using Cox regression models, 51 on 17 February 2020 at University of Edinburgh. Protected by copyright. http://www.bmj.com/ BMJ: first published as 10.1136/bmj.m131 on 12 February 2020. Downloaded from adjusting effect estimates for age and sex. In these survival analyses, we censored individuals according to the date of death or the end of followup (14 February 2011 in HSE, 31 December 2009 in SHS, 22 February 2016 for UK Biobank), whichever came first. To quantify the difference between the hazard ratios in each of the two studies, we calculated a ratio of the hazard ratio as we have done in other contexts 50 (HSESHS was the referent). We used Stata version 15 for all analyses.
Patient involvement
These analyses are based on existing data of typically healthy populations, and we were not involved in their recruitment. Thus, to our knowledge, no patients were explicitly engaged in designing the present research question or the outcome measures, nor were they involved in developing plans for recruitment, design, or implementation of the study. No patients were asked to advise on interpretation or writing up of results. Results from UK Biobank are routinely disseminated to study participants via the study website and social media outlets.
results
In table 1 (biomedical factors) and supplemental figure 1 (demographic, social, and behavioural factors plus drug use), we compare the baseline characteristics of participants in UK Biobank against those in the compilation of 18 cohort studies. UK Biobank study members were less likely to have had a subuniversity level education, to be living alone or unmarried, to be sedentary, to have existing cardiovascular disease, or to be taking drug treatments for raised blood glucose, although the reverse was seen for lipid lowering and antihypertensive drugs. In analyses restricted to study members not reporting the use of such therapies, we essentially observed no marked difference between studies members for total and high density lipoprotein cholesterol or for glycated haemoglobin. Whereas values for C reactive protein were lower in UK Biobank, both systolic and diastolic blood pressure were somewhat higher. Taken together, UK Biobank participants had a generally more favourable risk factor profile.
In UK Biobank, 14 288 deaths from all causes occurred during an average of 7.0 years of follow up in 499 701 people who consented to be linked to mortality registers. In the combined HSESHS databases, 10 years of mortality surveillance gave rise to 7861 deaths in 89 895 people with these consents. Of the five mortality categories examined in survival analyses, rates of cardiovascular disease, all cancers combined, and tobacco and obesity attributable cancers were markedly lower in UK Biobank, whereas the rate of suicide was higher (supplemental table 2).
In figure 1 , for each study, we depict the association of known baseline demographic and behavioural risk factors with cardiovascular disease mortality. The expected direction of association was the same in both studies for the seven characteristics, whereby being male, being of higher age, being physically inactive, not drinking alcohol, not being married or cohabiting, being a current or former smoker, and not having a higher education degree were related to elevated rates of cardiovascular disease mortality. Some modest differences existed in the magnitude of these effects in four of the risk factors examined, such that hazard ratios were typically higher in UK Biobank. When we explored the links between biomedical factors and cardiovascular disease mortality (fig 2) , all 10 of the biomarkers featured showed known associations with cardiovascular disease deaths in both studies. Although agreement between studies was again high, some heterogeneity was also apparent in the strength of these effects for higher levels of glycated haemoglobin, existing cardiovascular disease (stronger effects in UK Biobank than in HSESHS for both risk factors), and hypertension (the reverse). Taken together, a high degree of concordance existed for cardiovascular disease risk factor associations in UK Biobank and HSESHS.
Next, we examined the association of selected baseline factors with some noncardiovascular disease mortality outcomes, including different presentations of cancer deaths and completed suicides (fig 3) . Known risk factor associations were replicated across both studies. The magnitude of the association of cigarette smoking with lung cancer and malignancies causatively linked to tobacco intake were weaker for UK Biobank, whereas obesity and cancers attributed to it yielded similar effects in each study. Hazard ratios were also essentially the same for lower educational attainment and suicide, although statistical power was modest in these analyses, particularly for HSE SHS, as evidenced by the wide confidence intervals. Physical stature showed the predicted opposing and shallow gradients for cardiovascular disease (negative) and cancer (positive); again, effect sizes were very similar in both studies. Given well known secular changes in risk factors levels, as evidenced by repeat cross sectional surveys, 52 we used sensitivity analyses to explore the effect of having the same calendar period (2006 08) for recruitment of participants in HSE and UK Biobank (supplemental figure 2), and in another set of analyses we additionally aligned mortality surveillance by right censoring in UK Biobank (followup to 14 February 2011) (supplemental figure 3 ). Owing to a rarity of events, these analyses were restricted to death from cardiovascular disease. Risk factor associations were essentially the same as those apparent in the main analyses, the only exception being obesity. We also found that results held in sex specific analyses for demographic and behavioural characteristics (supplemental figure 4) and biomarkers (supplemental figure 5) . Lastly, given that, as described, the self reported use of drugs for lowering blood pressure and lipids was higher in members of UK Biobank relative to our comparator cohorts, we tested whether this was also evident for other health seeking behaviours such as vitamin and mineral supplementation. The prevalence of such use was counter to expectations, being lower in UK Biobank (21.8%) than in HSESHS (33.1%).
discussion
In a comparison of findings between UK Biobank and 18 studies from the HSESHS consortium, we found close agreement for a series of well established risk factors for cause specific mortality. These concordant results were apparent despite the response rate in UK Biobank being an order of magnitude lower than in the comparator cohorts and that study having a generally more favourable prevalence of sociodemographic, behavioural, and health related characteristics at baseline and lower rates of cause specific mortality during followup, as shown here and elsewhere. 24 Findings from other studies The only other analyses of risk factor relations in UK Biobank versus those in comparator studies of which we are aware are those for cardiometabolic 53 54 The goal of those papers, however, was discovery of risk factors rather than testing well established associations between risk factors and chronic disease. Blood based biomarkers in UK Biobank were also not available at the time of these analyses and, in the report featuring venous thromboembolism as the endpoint of interest, 54 interstudy comparison was hampered by differing approaches to disease ascertainment. As described, UK Biobank principal investigators, while acknowledging that their study has little value in describing the prevalence of a risk factor or rates of mortality-never stated objectives-have attempted to minimise unease around the investigation of chronic disease aetiology-its primary purpose-by arguing that generalisable associations with risk factors can be obtained in nonrepresentative samples provided sufficiently large numbers of people with a range of exposures are included. 11 25 26 They cite the circumstantial evidence of cohort studies drawing on selected populations that have markedly higher response rates than UK Biobank-Framingham resi dents, 27 British physicians, 55 US nurses 56 -all of which produced results that have subsequently been shown to be transportable to general population based studies and have contributed much to the prevention of cardiovascular disease and selected cancers. Similarly, our findings mirror those from analyses in which we have compared risk factors for coronary heart disease in another highly select group, a cohort of British Hazard ratios are adjusted for age and sex. squares indicate hazard ratios and error bars denote 95% ci for relation of each characteristic with risk of death outcome. ratio of hazard ratios (rHr) summarises between study differences (Hse-sHs is reference group) for effect estimates for each outcome. Distributions of glycated haemoglobin (Hba 1c ), c reactive protein, and high density lipoprotein (HDl) cholesterol were skewed, so they were log 2 transformed and effect estimates reflect doubling for each biomarker. elevated waist:hip ratio was denoted by ≥0.90 for men and ≥0.85 for women; obesity was indicated by body mass index ≥30. Fev 1 =forced expiratory volume in one second civil servants (the Whitehall II prospective cohort study), with those from a cohort based on the general population (the British Regional Heart Study). 57 In those analyses, we also found near identical risk factor relations across studies.
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limitations of study
Our work inevitably has some shortcomings. Firstly, whereas UK Biobank includes people from the contiguous countries that comprise the UK, the comparator studies included no data from Wales. We have no reason to believe that the absence of these data would affect our results, however. Secondly, whereas core elements of data collection in the HSE SHS consortium were essentially constant across studies, scientific themes for data collection differed from year to year. 40 As such, selected biomedical data were not collected in all survey years and the analytical sample size was diminished as a result. Thirdly, for two variables-physical activity and alcohol intakebaseline data were not directly comparable between studies, although we were able to harmonise data into binary groups. These represent two of 23 risk factoroutcome combinations, however, which means that exclusion of these data would have no effect on our overall conclusions of high agreement between studies. Fourthly, the mode of data collection differed between studies-data collection in UK Biobank took place in designated research centres, whereas it was home based in HSESHS-although we see no strong justification for this affecting our results. Fifthly, in the main analyses, the endpoint of the interest was cardiovascular disease mortality, which is an amalgam of both incidence of the condition and survival with it. This raises the question of whether risk factor effects differ for incidence, which is temporally closer to assessment of exposure than is death. However, comparison of risk factors for coronary heart disease and stroke, as ascertained from mortality records and hospital admissions (incidence), have shown no evidence of differential associations. 58 We thank participants in the studies featured in this manuscript.
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